These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Treating mild-to-moderate hypertension: a comparison of lisinopril-hydrochlorothiazide fixed combination with captopril and hydrochlorothiazide free combination.
    Author: Graham RD.
    Journal: J Hum Hypertens; 1991 Dec; 5 Suppl 2():59-60; discussion 61. PubMed ID: 1665179.
    Abstract:
    The fixed combination comprising lisinopril 10 mg and hydrochlorothiazide 12.5 mg once daily (L/HCTZ) was compared with captopril 25 mg and hydrochlorothiazide 25 mg once daily (C/HCTZ) in a randomized, double-blind, parallel-group study. After a 2-4 week placebo run-in period patients were randomized to L/HCTZ (n = 82) or C/HCTZ (n = 83) for 8 weeks. After 8 weeks, peak blood levels of both treatments showed lowered sitting BPs (-22.8/-14.3 mm Hg for L/HCTZ vs -22.8/-14.0 mm Hg for C/HCTZ), and standing BPs (-22.6/-13.1 mm Hg vs -21.6/-12.8 mm Hg, respectively). Between-drug differences were not significant (ns). At trough blood levels L/HCTZ lowered sitting BPs more than C/HCTZ, -23.6/-14.9 mm Hg vs -16.0/-11.3 mm Hg (P less than 0.02/less than 0.03), respectively. The effect on standing BP was similar, -22.0/-13.8 mm Hg vs -15.1/-10.3 mm Hg (P less than 0.03/less than 0.05) for L/HCTZ and C/HCTZ, respectively. Both treatments slightly increased heart rate (ns). Serum potassium fell more with C/HCTZ than with L/HCTZ (P less than 0.005). The fasting glucose level rose with L/HCTZ and fell with C/HCTZ. Uric acid, triglycerides and fasting cholesterol levels rose in both groups (ns). There were no differences between treatments with respect to adverse events. L/HCTZ appears to be a well-tolerated combination with efficacy on once-daily dosing superior to that of C/HCTZ.
    [Abstract] [Full Text] [Related] [New Search]